(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of -0.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Nanobiotix Sa's revenue in 2024 is $38,932,258.On average, 2 Wall Street analysts forecast NBTX's revenue for 2024 to be $1,579,202,155, with the lowest NBTX revenue forecast at $1,438,980,504, and the highest NBTX revenue forecast at $1,719,423,805. On average, 2 Wall Street analysts forecast NBTX's revenue for 2025 to be $3,670,743,585, with the lowest NBTX revenue forecast at $127,259,986, and the highest NBTX revenue forecast at $7,214,227,184.
In 2026, NBTX is forecast to generate $198,431,311 in revenue, with the lowest revenue forecast at $198,431,311 and the highest revenue forecast at $198,431,311.